2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1361

Utility of Rheumatoid Arthritis Impact of Disease (RAID) in Routine Care; Identification of Patients Achieving DAS28 Remission or Low Disease Activity, and Burden of Unmet Patient Reported Outcomes
Abstract Number: 1210

Utilization of a Multispecialty Team for the Diagnosis of Giant Cell Arteritis Reduces Patient Morbidity
Abstract Number: 2711

Utilization of Biologic Treatments in Oligoarticular and Polyarticular Juvenile Idiopathic Arthritis
Abstract Number: 1762

UV Light Induces Acute Type I Interferon Production in the Skin and Blood Which Is cGAS Dependent
Abstract Number: 81

UV Light Stimulates a Systemic Neutrophil Response Associated with Transient Kidney Injury
Abstract Number: 2481

Uveitis in 320 Patients with Psoriatic Arthritis. Epidemiology, Clinical Features and Biological Treatment: Study from a Single University Center
Abstract Number: 159

VA Musculoskeletal “Master Educator” Faculty Development Program for Health Professions Educators: Follow-Up on Changes in Educational Duties and Perceptions of Program Content
Abstract Number: 636

Validation and Transcultural Adaptation of the Spanish Version of Brief Index of Lupus Damage (BILD) Questionnaire
Abstract Number: 2338

Validation of a Claims Algorithm to Identify Interstitial Lung Disease in Patients with Rheumatoid Arthritis
Abstract Number: 443

Validation of a Risk Perception Questionnaire Developed for Patients with Rheumatoid Arthritis
Abstract Number: 415

Validation of a Satisfaction Measure for Use in Total Joint Replacement Clinical Trials
Abstract Number: 1915

Validation of a Serologic Antibody Biomarker Against a Candidate Gut Pathobiont for the Diagnosis of Lupus Nephritis
Abstract Number: 189

Validation of Claims-based Algorithms to Identify Interstitial Lung Disease in Patients with Rheumatoid Arthritis
Abstract Number: 44

Validation of New Genes Identified in a Molecular Bayesian Network of Rheumatoid Arthritis Synovitis
Abstract Number: 490

Validation of Risk Scores for Predicting Progression in Individuals “At Risk of Rheumatoid Arthritis”

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].